Clinical Commissioning Policy: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

NHS England has reviewed evidence for vonicog alfa and concluded that it is not for routine commissioning for the treatment and prevention of bleeding in adults with von Willebrand disease.

NHS England